Charles River Laboratories International, Inc. Share Price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:04:40 05/12/2024 GMT 5-day change 1st Jan Change
193.61 USD -2.88% Intraday chart for Charles River Laboratories International, Inc. -2.81% -18.16%
Capitalization 10.19B 9.68B 9B 8.02B 14.35B 864B 15.84B 111B 41.41B 354B 38.28B 37.45B 1,531B P/E ratio 2024 *
34.2x
P/E ratio 2025 * 30x
Enterprise value 12.29B 11.67B 10.86B 9.67B 17.3B 1,041B 19.1B 134B 49.94B 427B 46.17B 45.16B 1,846B EV / Sales 2024 *
3.05x
EV / Sales 2025 * 2.87x
Free-Float
97.96%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.76%
1 week-0.88%
Current month-0.88%
1 month+4.57%
3 months+3.20%
6 months-8.71%
Current year-16.54%
More quotes
1 week
196.61
Extreme 196.6139
203.01
1 month
183.35
Extreme 183.35
230.02
Current year
176.48
Extreme 176.48
275.00
1 year
176.48
Extreme 176.48
275.00
3 years
161.65
Extreme 161.65
379.65
5 years
95.58
Extreme 95.58
460.21
10 years
59.99
Extreme 59.99
460.21
More quotes
Director TitleAgeSince
Chief Executive Officer 73 31/12/1991
Director of Finance/CFO 51 30/04/2022
Chief Tech/Sci/R&D Officer - 31/12/2013
Manager TitleAgeSince
Director/Board Member 76 31/12/2002
Chairman 73 31/12/1999
Director/Board Member 67 28/10/2008
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.76%-0.88%-0.52%-43.85%10.19B
-1.80%-0.19%+55.60%-26.45%43.21B
-1.31%+0.29%-6.01%-23.44%36.88B
-1.09%+1.80%+11.32%-8.79%26.71B
-1.88%+0.78%-21.37%-20.32%17.71B
-0.12%+0.96%+55.66%+98.21%16.71B
+3.40%-1.79%-45.98%-84.06%16.02B
-1.38%+0.90%+18.11%-35.04%12.06B
-2.42%+0.17%+23.26%+66.46%10.74B
-0.73%+0.46%+3.05%-20.72%9.73B
Average -0.91%-0.07%+9.31%-9.80% 20B
Weighted average by Cap. -1.02%+0.07%+13.96%-13.32%
See all sector performances

Financials

2024 *2025 *
Net sales 4.03B 3.83B 3.56B 3.17B 5.67B 342B 6.26B 44.07B 16.38B 140B 15.14B 14.81B 605B 4.11B 3.91B 3.63B 3.24B 5.79B 349B 6.39B 44.97B 16.71B 143B 15.45B 15.11B 618B
Net income 302M 287M 267M 237M 425M 25.57B 469M 3.3B 1.23B 10.49B 1.13B 1.11B 45.32B 342M 325M 302M 269M 482M 29.01B 532M 3.74B 1.39B 11.9B 1.29B 1.26B 51.41B
Net Debt 2.1B 1.99B 1.85B 1.65B 2.96B 178B 3.26B 22.95B 8.53B 72.97B 7.89B 7.71B 315B 1.63B 1.55B 1.44B 1.28B 2.3B 138B 2.54B 17.84B 6.63B 56.7B 6.13B 5.99B 245B
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Employees
21,100
More about the company
Date Price Change Volume
05/12/24 193.73 $ -2.82% 182,760
04/12/24 199.35 $ +0.03% 436,620
03/12/24 199.30 $ -0.97% 458,614
02/12/24 201.25 $ +1.10% 630,456
29/11/24 199.06 $ -0.27% 287,759

Delayed Quote Nyse, December 05, 2024 at 03:06 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart CHARLES-RIVER-LABORATORIEMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
199.35USD
Average target price
216.27USD
Spread / Average Target
+8.49%
Consensus

Quarterly revenue - Rate of surprise